Chocolate Recalled Nationwide Due to Potential 'Life-Threatening Allergic Reaction': Here's What You Need to Know
A nationwide recall has been issued for JLM-brand Dark Chocolate Nonpareils due to a risk of 'serious or life-threatening allergic reaction," per the FDA
The recall occurred after it was discovered that batches of the product may contain 'undeclared milk'
No illnesses have currently been reported, and consumers who purchased the batches in question are urged to return them to the place of purchaseA nationwide recall has been issued for a common type of chocolate due to 'risk of serious or life-threatening allergic reaction,' according to the U.S. Food & Drug Administration (FDA).
Michigan-based Lipari Foods is recalling its 14-ounce packages of JLM Branded 'Dark Chocolate Nonpareils" as they may contain "undeclared milk," per an announcement posted on the FDA's website on Friday, June 20.
'People who have allergies to milk run the risk of serious or life-threatening allergic reaction if they consume these products,' the announcement said.
According to the FDA, the Dark Chocolate Nonpareils were distributed nationwide and also come in 14-ounce clear plastic tubs.
The tubs in question will be marked with one of the following lot numbers on the label: 28202501A, 29202501A, 23202504A, 14202505A, 15202505A or 03202506A.
No illnesses have been reported to date in connection with the recall, per the FDA. The organization additionally said that the recall occurred after Lipari Foods was notified of the error by the Pennsylvania-based Weaver Nut Company, which distributes and manufactures candy and nuts.
The FDA is urging customers who have purchased the 14-ounce packages to return them to the place of purchase 'for a full refund.'
PEOPLE reached out to Lipari Foods for comment on Saturday, June 21, but did not receive an immediate response.
This isn't the first time that a nationwide recall of chocolate has been issued in recent months. In December 2024, Cal Yee Farms' recalled some of its chocolate products due to the fact that they potentially contained 'undeclared milk, soy, wheat, sesame, FD&C #6 and almonds.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
The FDA heightened the risk level of the recall earlier this year in January, after it was discovered that the products may also contain undeclared milk.
Read the original article on People
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Quote of the Day: ‘I Feel Like I've Been Lied To': When a Measles Outbreak Hits Home
'It's still spreading. I'm starting to think this thing has come back to stay.' LYNN DOUGLAS, the nursing director of the Williston Basin School District in North Dakota, on an outbreak of measles, a disease that had not been present in the state in 14 years. Measles has also hit other parts of the U.S.
Yahoo
2 hours ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
3 hours ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
